Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
    (Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
    (Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
    (Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
    Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
    ... Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
    ... Institute of Standards and Technology (NIST) have demonstrated a ... for a wide variety of fields dealing with things ... a few nanoliters. Currently a table-top prototype, the NIST ... studying minute quantities of complex materials that must function ...
    ... (Nasdaq: MATK ) today announced its financial results ... third quarter were $117.2 million, up 51% from $77.8 million ... was $11.9 million, or $0.35 per diluted share, for the ... to $8.9 million, or $0.27 per diluted share, for the ...
    Cached Biology Technology:EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 2EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 3EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 4EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 5EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 6EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 7Micro rheometer is latest Lab On a Chip device 2Martek Announces Third Quarter FY 2010 Financial Results 2Martek Announces Third Quarter FY 2010 Financial Results 3Martek Announces Third Quarter FY 2010 Financial Results 4Martek Announces Third Quarter FY 2010 Financial Results 5Martek Announces Third Quarter FY 2010 Financial Results 6Martek Announces Third Quarter FY 2010 Financial Results 7Martek Announces Third Quarter FY 2010 Financial Results 8Martek Announces Third Quarter FY 2010 Financial Results 9Martek Announces Third Quarter FY 2010 Financial Results 10Martek Announces Third Quarter FY 2010 Financial Results 11Martek Announces Third Quarter FY 2010 Financial Results 12Martek Announces Third Quarter FY 2010 Financial Results 13Martek Announces Third Quarter FY 2010 Financial Results 14
    (Date:4/20/2014)... analysis growing in importance for both basic researchers ... and the University of Maryland have developed a ... of gene activity from RNA sequencing (RNA-seq) data., ... famously speedy fish, estimates of gene expression that ... a few minutes, with accuracy that equals or ...
    (Date:4/20/2014)... a gift of germsgerms that help to kick-start ... fend off infection, may paradoxically interrupt a newborn,s ... susceptible to dangerous pathogens. , A new ... Hospital of Philadelphia (CHOP) sheds light on immunology ... a crucial role in fostering the rapid production ...
    (Date:4/20/2014)... 20, 2014 -- Using corn crop residue to make ... generate more greenhouse gases than gasoline, according to a ... Change . , The findings by a University of ... residue can be used to meet federal mandates to ... , Corn stover -- the stalks, leaves and cobs ...
    Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3
    ... the first broad-spectrum drugs to combat human rhinoviruses (HRVs), ... on these potential drugs for infections that include the ... Chemistry Letters . Angus MacLeod and colleagues ... they can lead to dangerous complications for millions of ...
    ... research from the University of Guelph, published Tuesday in ... allowing industrial extraction in a northern Ontario old-growth red ... would significantly threaten biodiversity in Canada. The ... "scientifically irreplaceable system." "Wolf Lake Forest deserves intensive ...
    ... atmospheric circulation in the southern Australian-New Zealand region has ... the Nature journal Scientific Reports , ... pushed further into the Southern Ocean by rising global ... frequent occurrences of strong El Nios in recent decades, ...
    Cached Biology News:New research: Wolf Lake ancient forest is endangered ecosystem 2New research: Wolf Lake ancient forest is endangered ecosystem 3Climate tug of war disrupting Australian atmospheric circulation patterns 2
    ... 301 Power Supply, 1. 300 V, ... or constant current modes.Single-unit increments in ... reproducibility.Suitable for submarine, mini vertical, and ... as semidry and mini tank blotting ...
    Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
    B3-1...
    Mouse TrkC Affinity Purified Polyclonal Ab...
    Biology Products: